BINSA Act
Rep. Moolenaar and Rep. Dingell Introduce Bipartisan Bill to Restrict U.S. Biotech Investment in China
The BINSA Act is currently in the early stages of the legislative process. It was recently sent to the House Committee on Financial Services for review. There are no upcoming votes scheduled at this time.
Legislative Progress
This bill has strong bipartisan support and builds on previous laws targeting Chinese biotech. However, it may face pushback from large drug companies that rely on international partnerships.
Key Points
Impact Analysis
Personal Impact
Life & Work
U.S. biotech startups and small pharma companies that rely on partnerships, licensing deals, or joint ventures with Chinese firms would face new restrictions or outright bans on those transactions. For smaller companies with limited resources, losing access to cheaper Chinese manufacturing or development partners could raise costs, slow drug development timelines, and reduce competitive options.
“give particular consideration to licensing transactions, joint ventures, and equity investments involving drug discovery platforms, clinical development capabilities, and biologics manufacturing as priority categories for both the prohibited and notifiable technology tiers within the biotechnology sector”
Disabilities
Activities
Milestones
Referred to the House Committee on Financial Services.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
BINSA Act
Data Sources
Sponsor
Cosponsors
(1)Analysis generated by AI. Always verify with official sources.